 | • レポートコード：MRC2-11QY12656 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は代謝障害治療薬のグローバル市場について調査・分析したレポートです。種類別（異染性白質ジストロフィー、球状白質ジストロフィー、肝性脳症、その他）市場規模、用途別（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別代謝障害治療薬の競争状況、市場シェア ・世界の代謝障害治療薬市場：種類別市場規模 2015年-2020年（異染性白質ジストロフィー、球状白質ジストロフィー、肝性脳症、その他） ・世界の代謝障害治療薬市場：種類別市場規模予測 2021年-2026年（異染性白質ジストロフィー、球状白質ジストロフィー、肝性脳症、その他） ・世界の代謝障害治療薬市場：用途別市場規模 2015年-2020年（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症、その他） ・世界の代謝障害治療薬市場：用途別市場規模予測 2021年-2026年（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症、その他） ・北米の代謝障害治療薬市場分析：米国、カナダ ・ヨーロッパの代謝障害治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの代謝障害治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の代謝障害治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの代謝障害治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AbbVie、Novo Nordisk、Actelion Pharmaceuticals、Sanofi、Biocon、Merck、Boehringer Ingelheim、AstraZeneca、CymaBay Therapeutics、Eli Lilly and Company ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Metabolic Disorders Therapeutics is a drug used to treat the symptoms of metabolic disorders caused by a variety of causes.
Due to the increasing pressure of modern life and the spread of unhealthy lifestyles, the global metabolic disorder treatment market will continue to grow strongly during the forecast period.
Market Analysis and Insights: Global Metabolic Disorders Therapeutics Market
The global Metabolic Disorders Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Metabolic Disorders Therapeutics Scope and Market Size
Metabolic Disorders Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Metabolic Disorders Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AbbVie
Novo Nordisk
Actelion Pharmaceuticals
Sanofi
Biocon
Merck
Boehringer Ingelheim
AstraZeneca
CymaBay Therapeutics
Eli Lilly and Company
Market segment by Type, the product can be split into
Metachromatic Leukodystrophy
Globoid Leukodystrophy
Hepatic Encephalopathy
Others
Market segment by Application, split into
Diabetes
Obesity
Hypercholesterolemia
Lysosomal Storage Diseases
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Metabolic Disorders Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Metachromatic Leukodystrophy
1.4.3 Globoid Leukodystrophy
1.4.4 Hepatic Encephalopathy
1.4.5 Others
1.5 Market by Application
1.5.1 Global Metabolic Disorders Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Diabetes
1.5.3 Obesity
1.5.4 Hypercholesterolemia
1.5.5 Lysosomal Storage Diseases
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disorders Therapeutics Market Perspective (2015-2026)
2.2 Global Metabolic Disorders Therapeutics Growth Trends by Regions
2.2.1 Metabolic Disorders Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Metabolic Disorders Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Metabolic Disorders Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Metabolic Disorders Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Metabolic Disorders Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorders Therapeutics Players by Market Size
3.1.1 Global Top Metabolic Disorders Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Metabolic Disorders Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Metabolic Disorders Therapeutics Market Concentration Ratio
3.2.1 Global Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Metabolic Disorders Therapeutics Revenue in 2019
3.3 Metabolic Disorders Therapeutics Key Players Head office and Area Served
3.4 Key Players Metabolic Disorders Therapeutics Product Solution and Service
3.5 Date of Enter into Metabolic Disorders Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Metabolic Disorders Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
5.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Metabolic Disorders Therapeutics Market Size (2015-2020)
6.2 Metabolic Disorders Therapeutics Key Players in North America (2019-2020)
6.3 North America Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
6.4 North America Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Metabolic Disorders Therapeutics Market Size (2015-2020)
7.2 Metabolic Disorders Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
7.4 Europe Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Metabolic Disorders Therapeutics Market Size (2015-2020)
8.2 Metabolic Disorders Therapeutics Key Players in China (2019-2020)
8.3 China Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
8.4 China Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Metabolic Disorders Therapeutics Market Size (2015-2020)
9.2 Metabolic Disorders Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
9.4 Japan Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Metabolic Disorders Therapeutics Market Size (2015-2020)
10.2 Metabolic Disorders Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Metabolic Disorders Therapeutics Market Size (2015-2020)
11.2 Metabolic Disorders Therapeutics Key Players in India (2019-2020)
11.3 India Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
11.4 India Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Metabolic Disorders Therapeutics Market Size (2015-2020)
12.2 Metabolic Disorders Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AbbVie
13.1.1 AbbVie Company Details
13.1.2 AbbVie Business Overview
13.1.3 AbbVie Metabolic Disorders Therapeutics Introduction
13.1.4 AbbVie Revenue in Metabolic Disorders Therapeutics Business (2015-2020))
13.1.5 AbbVie Recent Development
13.2 Novo Nordisk
13.2.1 Novo Nordisk Company Details
13.2.2 Novo Nordisk Business Overview
13.2.3 Novo Nordisk Metabolic Disorders Therapeutics Introduction
13.2.4 Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.2.5 Novo Nordisk Recent Development
13.3 Actelion Pharmaceuticals
13.3.1 Actelion Pharmaceuticals Company Details
13.3.2 Actelion Pharmaceuticals Business Overview
13.3.3 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Introduction
13.3.4 Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.3.5 Actelion Pharmaceuticals Recent Development
13.4 Sanofi
13.4.1 Sanofi Company Details
13.4.2 Sanofi Business Overview
13.4.3 Sanofi Metabolic Disorders Therapeutics Introduction
13.4.4 Sanofi Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.4.5 Sanofi Recent Development
13.5 Biocon
13.5.1 Biocon Company Details
13.5.2 Biocon Business Overview
13.5.3 Biocon Metabolic Disorders Therapeutics Introduction
13.5.4 Biocon Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.5.5 Biocon Recent Development
13.6 Merck
13.6.1 Merck Company Details
13.6.2 Merck Business Overview
13.6.3 Merck Metabolic Disorders Therapeutics Introduction
13.6.4 Merck Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.6.5 Merck Recent Development
13.7 Boehringer Ingelheim
13.7.1 Boehringer Ingelheim Company Details
13.7.2 Boehringer Ingelheim Business Overview
13.7.3 Boehringer Ingelheim Metabolic Disorders Therapeutics Introduction
13.7.4 Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.7.5 Boehringer Ingelheim Recent Development
13.8 AstraZeneca
13.8.1 AstraZeneca Company Details
13.8.2 AstraZeneca Business Overview
13.8.3 AstraZeneca Metabolic Disorders Therapeutics Introduction
13.8.4 AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.8.5 AstraZeneca Recent Development
13.9 CymaBay Therapeutics
13.9.1 CymaBay Therapeutics Company Details
13.9.2 CymaBay Therapeutics Business Overview
13.9.3 CymaBay Therapeutics Metabolic Disorders Therapeutics Introduction
13.9.4 CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.9.5 CymaBay Therapeutics Recent Development
13.10 Eli Lilly and Company
13.10.1 Eli Lilly and Company Company Details
13.10.2 Eli Lilly and Company Business Overview
13.10.3 Eli Lilly and Company Metabolic Disorders Therapeutics Introduction
13.10.4 Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.10.5 Eli Lilly and Company Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Metabolic Disorders Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Metabolic Disorders Therapeutics Revenue
Table 3. Ranking of Global Top Metabolic Disorders Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Metachromatic Leukodystrophy
Table 6. Key Players of Globoid Leukodystrophy
Table 7. Key Players of Hepatic Encephalopathy
Table 8. Key Players of Others
Table 9. Global Metabolic Disorders Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Metabolic Disorders Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Metabolic Disorders Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Metabolic Disorders Therapeutics Market Share by Regions (2015-2020)
Table 13. Global Metabolic Disorders Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Metabolic Disorders Therapeutics Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Metabolic Disorders Therapeutics Market Growth Strategy
Table 19. Main Points Interviewed from Key Metabolic Disorders Therapeutics Players
Table 20. Global Metabolic Disorders Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 21. Global Metabolic Disorders Therapeutics Market Share by Players (2015-2020)
Table 22. Global Top Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorders Therapeutics as of 2019)
Table 23. Global Metabolic Disorders Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Metabolic Disorders Therapeutics Product Solution and Service
Table 26. Date of Enter into Metabolic Disorders Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 29. Global Metabolic Disorders Therapeutics Market Size Share by Type (2015-2020)
Table 30. Global Metabolic Disorders Therapeutics Revenue Market Share by Type (2021-2026)
Table 31. Global Metabolic Disorders Therapeutics Market Size Share by Application (2015-2020)
Table 32. Global Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 33. Global Metabolic Disorders Therapeutics Market Size Share by Application (2021-2026)
Table 34. North America Key Players Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 36. North America Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. North America Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 38. North America Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 39. North America Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 40. Europe Key Players Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 42. Europe Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 44. Europe Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 46. China Key Players Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 47. China Key Players Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 48. China Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 49. China Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 50. China Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 51. China Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 52. Japan Key Players Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 54. Japan Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 56. Japan Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 60. Southeast Asia Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 62. Southeast Asia Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 64. India Key Players Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 65. India Key Players Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 66. India Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 67. India Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 68. India Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 69. India Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Metabolic Disorders Therapeutics Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Metabolic Disorders Therapeutics Market Share (2019-2020)
Table 72. Central & South America Metabolic Disorders Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Metabolic Disorders Therapeutics Market Share by Type (2015-2020)
Table 74. Central & South America Metabolic Disorders Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Metabolic Disorders Therapeutics Market Share by Application (2015-2020)
Table 76. AbbVie Company Details
Table 77. AbbVie Business Overview
Table 78. AbbVie Product
Table 79. AbbVie Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 80. AbbVie Recent Development
Table 81. Novo Nordisk Company Details
Table 82. Novo Nordisk Business Overview
Table 83. Novo Nordisk Product
Table 84. Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 85. Novo Nordisk Recent Development
Table 86. Actelion Pharmaceuticals Company Details
Table 87. Actelion Pharmaceuticals Business Overview
Table 88. Actelion Pharmaceuticals Product
Table 89. Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 90. Actelion Pharmaceuticals Recent Development
Table 91. Sanofi Company Details
Table 92. Sanofi Business Overview
Table 93. Sanofi Product
Table 94. Sanofi Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 95. Sanofi Recent Development
Table 96. Biocon Company Details
Table 97. Biocon Business Overview
Table 98. Biocon Product
Table 99. Biocon Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 100. Biocon Recent Development
Table 101. Merck Company Details
Table 102. Merck Business Overview
Table 103. Merck Product
Table 104. Merck Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 105. Merck Recent Development
Table 106. Boehringer Ingelheim Company Details
Table 107. Boehringer Ingelheim Business Overview
Table 108. Boehringer Ingelheim Product
Table 109. Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 110. Boehringer Ingelheim Recent Development
Table 111. AstraZeneca Business Overview
Table 112. AstraZeneca Product
Table 113. AstraZeneca Company Details
Table 114. AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 115. AstraZeneca Recent Development
Table 116. CymaBay Therapeutics Company Details
Table 117. CymaBay Therapeutics Business Overview
Table 118. CymaBay Therapeutics Product
Table 119. CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 120. CymaBay Therapeutics Recent Development
Table 121. Eli Lilly and Company Company Details
Table 122. Eli Lilly and Company Business Overview
Table 123. Eli Lilly and Company Product
Table 124. Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2015-2020) (Million US$)
Table 125. Eli Lilly and Company Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Disorders Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Metachromatic Leukodystrophy Features
Figure 3. Globoid Leukodystrophy Features
Figure 4. Hepatic Encephalopathy Features
Figure 5. Others Features
Figure 6. Global Metabolic Disorders Therapeutics Market Share by Application: 2020 VS 2026
Figure 7. Diabetes Case Studies
Figure 8. Obesity Case Studies
Figure 9. Hypercholesterolemia Case Studies
Figure 10. Lysosomal Storage Diseases Case Studies
Figure 11. Others Case Studies
Figure 12. Metabolic Disorders Therapeutics Report Years Considered
Figure 13. Global Metabolic Disorders Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Metabolic Disorders Therapeutics Market Share by Regions: 2020 VS 2026
Figure 15. Global Metabolic Disorders Therapeutics Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Metabolic Disorders Therapeutics Market Share by Players in 2019
Figure 18. Global Top Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorders Therapeutics as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Metabolic Disorders Therapeutics Revenue in 2019
Figure 20. North America Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Metabolic Disorders Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
ペプチド代謝障害治療薬の世界市場（～2026年） A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive. Peptide therapeutics are used to treat metabolic disorders owing to their stability, effici…- グロボイド細胞白質ジストロフィー（GLD）治療の世界市場（～2026年） Market Analysis and Insights: Global Globoid Cell Leukodystrophy Treatment Market The global Globoid Cell Leukodystrophy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Globoid Cell Leukodystrophy Treatment S…
- 肝性脳症（HE）治療薬の世界市場（～2026年） HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood. The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutic…
- ペプチド胃腸障害治療薬の世界市場（～2026年） Gastrointestinal disorders refer to diseases involving the gastrointestinal tract, namely the esophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, gallbladder, and pancreas. Market Analysis and Insights: Global Peptide Based Gastrointesti…
- 異染性白質ジストロフィー（MLD）治療の世界市場（～2026年） Market Analysis and Insights: Global Metachromatic Leukodystrophy (MLD) Treatment Market The global Metachromatic Leukodystrophy (MLD) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Metachromatic Leukodystro…